Abbreviations

AACR

American Association for Cancer Research

ADME

Absorption, distribution, metabolism and excretion

AR

Adaptive randomisation

ASCO

American Society of Clinical Oncology

AUC

Area under the curve

BOR

Best overall response

CENTRAL

Cochrane Central Register of Controlled Trials

CI

Confidence interval

CLL

Chronic lymphoid leukaemia

Cmax

Maximum serum concentration

CMF

Cyclophosphamide, methotrexate and 5-fluorouracil regimen

COMET

Core Outcome Measures in Effectiveness Trials

COS

Core outcome set

CR

Complete response

CR30

Complete response at 30 months

CRC

Colorectal cancer

CT

Computed tomography

DCIS

Ductal carcinoma in situ

DCO

Death certificate only

DFS

Disease-free survival

DoR

Duration of response

DSS

Disease-specific survival

ECCO

European Cancer Organisation

ECOG

Eastern Cooperative Oncology Group

EFS

Event-free survival

EFS24

Event-free survival at 24 months

EMA

European Medicines Agency

ENCR

European Network of Cancer Registries

EORTC

European Organisation for Research and Treatment of Cancer

ESMO

European Society for Medical Oncology

EU

European Union

FDA

Food and Drug Administration

FDG-PET

Fludeoxyglucose–positron emission tomography

FLASH

GCP

Good Clinical Practice

G-CSF

Granulocyte-colony stimulating factor

GEMMs

Genetically engineered mouse models

GI

Gastrointestinal

GLP

Good Laboratory Practice

GMP

Good Manufacturing Practice

GRADE

Grading of Recommendations, Assessment, Development and Evaluation

HBV

Hepatitis B virus

HIPEC

Hyperthermic intraperitoneal chemotherapy

HR

Hazard ratio

HR-QoL

Health-related quality of life

HRT

Hormone replacement therapy

HTS

High throughput screening

IACR

International Association of Cancer Registries

IARC

International Agency for Research on Cancer

ICD-O

International Classification of Diseases for Oncology

LMS

Leiomyosarcoma

MAMS

Multi-arm, multistage

MISCAN

MIcrosimulation SCreening ANalysis

mRCC

Metastatic renal cell carcinoma

MRD

Minimal residual disease

MTD

Maximum tolerated dose

NCI

National Cancer Institute

NNS

Number needed to screen

NSCLC

Non-small cell lung cancer

OBD

Optimum biological dose

OR

Odds ratio

ORR

Objective/overall response rate

OS

Overall survival

PET

Positron emission tomography

PFS

Progression-free survival

PICO

Population, Interventions or exposures, Comparators and Outcomes

PORT

Postoperative radiotherapy

PPR

Prior pelvic irradiation

PR

Partial response

PROM

Patient-Reported Outcome Measures

PULA

Previously Untreated, Locally Advanced Task Force

PVNS

Pigmented villonodular synovitis

RCT

Randomised controlled trial

RoB

Risk of Bias

RR

Relative risk, Risk ratio

SD

Standard deviation

SLL

Small lymphocytic lymphoma

STROBE

Strengthening the Reporting of Observational Studies in Epidemiology

STS

Soft tissue sarcoma

T1/2

Half-life

TNM

Tumour, Node, Metastasis classification

TTF

Time to treatment failure

TTP

Time to progression

UICC

Union for International Cancer Control

US

United States

VEGF(R)

Vascular endothelial growth factor (receptor)

WHO

World Health Organization